Elite in Neuroendocrine Tumor

Jaroslaw B. Cwikla

30 Warszawska Str, 
Olsztyn, WN, PL 
Elite in Neuroendocrine Tumor
30 Warszawska Str, 
Olsztyn, WN, PL 
OverviewLocationsClinical Research

Overview

Jaroslaw Cwikla practices in Olsztyn, Poland. Mr. Cwikla is rated as an Elite expert by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pheochromocytoma, Carcinoid Syndrome, and Appendectomy.

His clinical research consists of co-authoring 87 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 62 articles and participated in 1 clinical trial in the study of Neuroendocrine Tumor.

Gender
Male

Locations

30 Warszawska Str, Olsztyn, WN 10082, Poland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicenter, Open-label Post Authorization Safety Study to Evaluate the Effect of LysaKare® Infusion on Serum Potassium Levels in GEP-NET Patients Eligible for Lutathera® Treatment
A Multicenter, Open-label Post Authorization Safety Study to Evaluate the Effect of LysaKare® Infusion on Serum Potassium Levels in GEP-NET Patients Eligible for Lutathera® Treatment
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: LysaKare
Study Phase: Phase 4
A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel®/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumour Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumours
A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel®/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumour Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumours
Enrollment Status: Terminated
Publish Date: July 06, 2022
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

87 Total Publications

Pelvic splenosis infiltrating the uterus and ovary.
Pelvic splenosis infiltrating the uterus and ovary.
Journal: Ginekologia polska
Published: October 13, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Cwikla's expertise for a condition
ConditionClose
View All 16 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile